-
Something wrong with this record ?
Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2) and gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy
M Beranek, P Kolar, S Tschoplova, K Kankova, A Vasku
Language English Country United States
NLK
Directory of Open Access Journals
from 1995
Free Medical Journals
from 1995
PubMed Central
from 2007
Europe PubMed Central
from 2007
Open Access Digital Library
from 2007-01-01
- MeSH
- Diabetic Retinopathy enzymology genetics pathology MeSH
- Adult MeSH
- Financing, Organized MeSH
- Genetic Variation MeSH
- Haplotypes MeSH
- Middle Aged MeSH
- Humans MeSH
- Matrix Metalloproteinase 2 genetics blood MeSH
- Matrix Metalloproteinase 9 genetics blood MeSH
- Sex Characteristics MeSH
- Disease Progression MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
PURPOSE: Matrix metalloproteinases (MMPs) are postulated to be involved in the development of retinal angiogenesis through the regulation of extracellular matrix. The objective of the present study was to test for a possible association of five single nucleotide polymorphisms (SNPs) in the MMP-2 gene and two polymorphisms in the MMP-9 gene with proliferative diabetic retinopathy (PDR) and to determine their plasma levels. METHODS: The study comprised 490 Caucasian participants, who were divided into three groups: diabetics with PDR, diabetics without PDR, and nondiabetics. Genotypes were detected by polymerase chain reactions followed by restriction analyses with specific endonucleases and their frequencies determined. Plasma levels of MMP-2 and MMP-9 proteins were analyzed by ELISA. RESULTS: Neither MMP-2 SNPs nor MMP-9 SNPs revealed significant association with PDR in single-locus comparisons; similarly, MMP-2 haplotype frequencies did not differ notably between groups, although the C-allele of the -1306C/T polymorphism and the C-allele containing haplotype (CGCG) in MMP-2 exhibited marginally significant association with PDR in males (p<0.05, p(corr)=NS). Both MMP-2 and MMP-9 plasma levels showed statistically significant differences among the studied groups (p<0.001 and p=0.001, respectively) with highest levels in the PDR group. MMP-2 plasma levels were markedly higher in carriers of either the -1306CC and -1306CT genotypes and (p=0.009) or CGCG haplotype (p=0.043). CONCLUSIONS: These findings indicate that genotype- and haplotype-specific effects on MMP-2 expression corresponding with its plasma levels may contribute to the susceptibility to PDR.
- 000
- 02114naa 2200457 a 4500
- 001
- bmc11003964
- 003
- CZ-PrNML
- 005
- 20121221105501.0
- 008
- 110303s2008 xxu e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Beránek, Michal. $7 xx0193695
- 245 10
- $a Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2) and gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy / $c M Beranek, P Kolar, S Tschoplova, K Kankova, A Vasku
- 314 __
- $a Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. mberanek@med.muni.cz
- 520 9_
- $a PURPOSE: Matrix metalloproteinases (MMPs) are postulated to be involved in the development of retinal angiogenesis through the regulation of extracellular matrix. The objective of the present study was to test for a possible association of five single nucleotide polymorphisms (SNPs) in the MMP-2 gene and two polymorphisms in the MMP-9 gene with proliferative diabetic retinopathy (PDR) and to determine their plasma levels. METHODS: The study comprised 490 Caucasian participants, who were divided into three groups: diabetics with PDR, diabetics without PDR, and nondiabetics. Genotypes were detected by polymerase chain reactions followed by restriction analyses with specific endonucleases and their frequencies determined. Plasma levels of MMP-2 and MMP-9 proteins were analyzed by ELISA. RESULTS: Neither MMP-2 SNPs nor MMP-9 SNPs revealed significant association with PDR in single-locus comparisons; similarly, MMP-2 haplotype frequencies did not differ notably between groups, although the C-allele of the -1306C/T polymorphism and the C-allele containing haplotype (CGCG) in MMP-2 exhibited marginally significant association with PDR in males (p<0.05, p(corr)=NS). Both MMP-2 and MMP-9 plasma levels showed statistically significant differences among the studied groups (p<0.001 and p=0.001, respectively) with highest levels in the PDR group. MMP-2 plasma levels were markedly higher in carriers of either the -1306CC and -1306CT genotypes and (p=0.009) or CGCG haplotype (p=0.043). CONCLUSIONS: These findings indicate that genotype- and haplotype-specific effects on MMP-2 expression corresponding with its plasma levels may contribute to the susceptibility to PDR.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a diabetická retinopatie $x enzymologie $x genetika $x patologie $7 D003930
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a genetická variace $7 D014644
- 650 _2
- $a haplotypy $7 D006239
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a matrixová metaloproteinasa 2 $x genetika $x krev $7 D020778
- 650 _2
- $a matrixová metaloproteinasa 9 $x genetika $x krev $7 D020780
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a pohlavní dimorfismus $7 D012727
- 650 _2
- $a financování organizované $7 D005381
- 700 1_
- $a Kolář, Petr, $d 1970- $7 xx0037722
- 700 1_
- $a Tschöplová, Svatava. $7 _AN033174
- 700 1_
- $a Kaňková, Kateřina, $d 1971- $7 mzk2003190820
- 700 1_
- $a Vašků, Anna, $d 1954- $7 mzk2006356130
- 773 0_
- $t Molecular Vision $w MED00008305 $g Roč. 14, č. 1 (2008), s. 1114-1121
- 910 __
- $a ABA008 $b x $y 6
- 990 __
- $a 20110413110159 $b ABA008
- 991 __
- $a 20121221105545 $b ABA008
- 999 __
- $a ok $b bmc $g 831304 $s 695988
- BAS __
- $a 3
- BMC __
- $a 2008 $b 14 $c 1 $d 1114-1121 $m Molecular vision $n Mol Vis $x MED00008305
- LZP __
- $a 2011-3B/irme